EZH2 and small cell lung carcinoma: Several clinical trials are currently investigating EZH2 inhibitors in advanced solid tumors, including SCLC, such as a phase I trial of Mevrometostat (NCT03460977) and a phase II trial of XNW5004 (NCT06022757), though results are still pending (88).